



# UNIVERSITÀ DI PARMA

## ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Determinants of neonatal hypoglycemia after antenatal administration of corticosteroids (ACS) for lung maturation: Data from two referral centers and review of the literature

This is the peer reviewed version of the following article:

*Original*

Determinants of neonatal hypoglycemia after antenatal administration of corticosteroids (ACS) for lung maturation: Data from two referral centers and review of the literature / di Pasquo, Elvira; Saccone, Gabriele; Angeli, Laura; Dall'Asta, Andrea; Borghi, Elena; Fieni, Stefania; Berghella, Vincenzo; Magnani, Cinzia; Frusca, Tiziana; Ghi, Tullio. - In: EARLY HUMAN DEVELOPMENT. - ISSN 0378-3782. - 143:(2020), p. 104984. [10.1016/j.earlhumdev.2020.104984]

*Availability:*

This version is available at: 11381/2872473 since: 2022-01-18T17:50:48Z

*Publisher:*

Elsevier Ireland Ltd

*Published*

DOI:10.1016/j.earlhumdev.2020.104984

*Terms of use:*

Anyone can freely access the full text of works made available as "Open Access". Works made available

*Publisher copyright*

note finali coverpage

(Article begins on next page)

## Manuscript Details

<b>Manuscript number</b>	EHD_2019_526_R1
<b>Title</b>	Determinants of neonatal hypoglycemia after Antenatal administration of Corticosteroids (ACS) for lung maturation: data from two referral Centers and review of the literature
<b>Article type</b>	Research Paper

### Abstract

Background: A correlation between ACS and neonatal hypoglycemia has been recently demonstrated. Aims: The aim of the study was to evaluate the determinants of neonatal hypoglycemia in women exposed to ACS for respiratory distress syndrome prevention. Material and Methods: Retrospective, multicenter, cohort study conducted in two Tertiary University Units. All fetuses delivered from 2016 to 2017 after ACS (two doses i.m. of Betamethasone 12 mg 24 hours apart) were considered eligible for the study purpose. The primary outcome was the incidence of hypoglycemia, defined as a glycemic value <45 mg/dl within the first 48 hours of neonatal life. The effect on neonatal glycaemia due to timing (interval from exposure to delivery) and type (single completed, single partial or repeated course) of ACS administration was also assessed. Results: Overall, 99 neonates met the inclusion criteria. Hypoglycemia occurred in 38/99 (38.4%) of the included newborns. Compared to normoglycemic neonates, those with hypoglycemia had lower gestational age at delivery (33,06 ±3,37 vs. 35,94± 3,17 grams; p<0,0001), lower birthweight (1747,28± 815,29 vs. 2499,24± 780,51 grams; p<0,0001), a shorter interval time from administration to delivery (1,85 ±2,59 vs. 3,34 ±3,39 weeks; p=0,02) and a higher incidence of single partial course (23,7 vs. 8,72%; p=0,03). Multivariate logistic regression found that only birthweight was significantly associated with neonatal hypoglycemia (OR 0,4 95% CI -1,16/-0,04; p<0,038). Conclusion: Hypoglycemia occurs in a large proportion of fetuses exposed to ACS independently from the type of exposure (single partial/ single completed) and from the time interval between ACS administration and delivery. Birthweight seems to be the strongest determinant for the occurrence neonatal hypoglycemia after antenatal administration of steroids for lung maturation.

**Keywords** corticosteroids; hypoglycemia; neonate; respiratory distress

**Corresponding Author** Tullio Ghi

**Corresponding Author's Institution** University of Parma

**Order of Authors** Elvira di Pasquo, Gabriele Saccone, Laura Angeli, Andrea Dall'Asta, Elena Borghi, Stefania Fieni, Vincenzo Berghella, Cinzia Magnani, Tiziana Frusca, Tullio Ghi

**Suggested reviewers** Giancarlo Gargano, Federica Bellussi, Gerard Visser

## Submission Files Included in this PDF

### File Name [File Type]

Cover letter 06.02.docx [Cover Letter]

reply to Rewievers EHD.docx [Response to Reviewers (without Author Details)]

Highlights 27.12.docx [Highlights]

Title page.doc [Title Page (with Author Details)]

ACS Main doc 05.02 TG.docx [Manuscript (without Author Details)]

Tables 29.11.docx [Table]

JPeds authorship agreement contribution.docx [Author Statement]

Suppl 1.docx [Supplementary Material]

To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'.

Dear editor,

We thank the reviewer for the suggestions.

The manuscript has been revised according to the comments.

I hope that this revised version of the paper will be accepted for publication in EHD.

Best regards,

Tullio Ghi

## Reviewer 1

**This is a non-randomised retrospective study on the effect of antenatal corticosteroids (AC) on the incidence of neonatal hypoglycaemia. In fact only cases with AC were studied, to determine risk factors for hypoglycemia in this population. Multivariate analysis showed that Low Birth weight was the only independent risk factor; the population was, however, small (n=99) and it seems likely that both short gestational age and low birth weight centile were the underlying factors (not addressed in the discussion)**

*R. We thank the reviewer for this comment. We fully agree with him about the fact that both gestational age and low birth weight are related with the incidence of neonatal hypoglycemia. In particular, both factors were statistically different at the univariate analysis between normoglycemic and hypoglycemic newborns but at multivariable analysis, the birthweight remained as the only independent and significant predictor of neonatal hypoglycemia. Of note, the regression model including gestational age at delivery did not demonstrate a significant association between this variable and neonatal hypoglycemia. (supplementary Table 1).*

*Our finding has been more extensively addressed in the discussion as requested by the reviewer*

**Hypoglycemia in non AC populations, or in overall preterm birth cohorts, were not addressed, but it seems likely that the same risk factors apply. I am sure there are data on neonatal hypoglycemia in preterm infants before the era of AC To me the most important information came from the literature summary (4 studies only), showing that there is indeed an increased incidence of neonatal hypoglycemia following AC. I wonder if in the Cochrane publications on AC, have obtained information on neonatal hypoglycemia.**

*R. Thank you for this smart comment that give us the opportunity to clarify some points. First of all, we agree with the reviewer about the existence of studies on the incidence of hypoglycemia in preterm infants before the era of AC; however, we did not include them in the references because in most cases they were studies published before 1990 and advances in perinatology have led to an improvement in the diagnosis, definition and management of neonatal hypoglycemia. Secondly, our aim was not to show the incidence of hypoglycaemia in preterm neonates, but rather we were interested in comparing this outcome between neonates exposed or not to antenatal steroids. Finally, the Cochrane publication by Roberts et al. published in 2017 did not take into consideration the occurrence of hypoglycemia in early preterms while this was addressed by the meta-analysis of Saccone et al. (2016) which*

*confirmed a significant association between AC and hypoglycaemia in near term and term neonates (RR 1.6)*

**Please add number of patients in summary**

*R. Thank you. The number of included patients has been added in the summary*

**In the introduction it is stated that the vast majority of women receiving AC do not deliver preterm. Please add references; this does not hold for all populations.**

*R. Thank you for this comment. In this regard, we have added a pertinent reference: Jobe AH, Goldenberg RL. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2018 Jul;219(1):62-74 (reference 3; cited as reference 25 on the previous version )*

**Second, that there is a cognitive and motor impairment after AC; is that really true ( references?)**

*R. We thank the reviewer for this comment. We added the appropriate reference (ref 6).*

## Highlights

- Hypoglycemia occurs in a large proportion of fetuses exposed to antenatal corticosteroids (ACS) independently from type of exposure (single partial/ single completed) and from interval from ACS administration to delivery.
- Birthweight seems to be the strongest risk factor for neonatal hypoglycemia.
- A strict glycaemic control is necessary for neonates exposed to ACS, in particular for those of low birthweight

FIGURE

**Determinants of neonatal hypoglycemia after Antenatal administration of Corticosteroids (ACS) for lung maturation: data from two referral Centers and review of the literature**

**Running title:** Neonatal hypoglycemia after corticosteroids

**Keywords:** corticosteroids, hypoglycemia, neonate, respiratory distress

**Abbreviation list**

ACS= antenatal Corticosteroids

IUGR= Intrauterine Growth Restriction

Abstract word count: 250

Main text word count: 2296

Table count: 4

Figure count: 0

## ABSTRACT

**Background:** A correlation between ACS and neonatal hypoglycemia has been recently demonstrated.

**Aims:** The aim of the study was to evaluate the determinants of neonatal hypoglycemia in women exposed to ACS for respiratory distress syndrome prevention.

**Material and Methods:** Retrospective, multicenter, cohort study conducted in two Tertiary University Units. All fetuses delivered from 2016 to 2017 after ACS (two doses i.m. of Betamethasone 12 mg 24 hours apart) were considered eligible for the study purpose. The primary outcome was the incidence of hypoglycemia, defined as a glycemic value  $\leq 45$  mg/dl within the first 48 hours of neonatal life. The effect on neonatal glycaemia due to timing (interval from exposure to delivery) and type (single completed, single partial or repeated course) of ACS administration was also assessed.

**Results:** Overall, 99 neonates met the inclusion criteria. Hypoglycemia occurred in 38/99 (38.4%) of the included newborns. Compared to normoglycemic neonates, those with hypoglycemia had lower gestational age at delivery ( $33,06 \pm 3,37$  vs.  $35,94 \pm 3,17$  grams;  $p < 0,0001$ ), lower birthweight ( $1747,28 \pm 815,29$  vs.  $2499,24 \pm 780,51$  grams;  $p < 0,0001$ ), a shorter interval time from administration to delivery ( $1,85 \pm 2,59$  vs.  $3,34 \pm 3,39$  weeks;  $p = 0,02$ ) and a higher incidence of single partial course ( $23,7$  vs.  $8,72\%$ ;  $p = 0,03$ ). Multivariate logistic regression found that only birthweight was significantly associated with neonatal hypoglycemia (OR 0,4 95% CI -1,16/-0,04;  $p < 0,038$ ).

**Conclusion:** Hypoglycemia occurs in a large proportion of fetuses exposed to ACS independently from the type of exposure (single partial/ single completed) and from the time interval between ACS administration and delivery. Birthweight seems to be the strongest determinant for the occurrence neonatal hypoglycemia after antenatal administration of steroids for lung maturation.

## **INTRODUCTION**

Antenatal corticosteroids administration (ACS) is the accepted standard of care for women at risk of preterm delivery due to their beneficial effects on neonatal morbidity and mortality (1). Following the demonstration of their clinical usefulness among the preterm neonates delivered **within 2 to 7 days from maternal administration (2)**, the use of steroids has started to be widely offered to all women deemed to be at risk of impending premature delivery. In our daily practice in fact the use of steroids turns out to be mostly inappropriate as the vast majority of fetuses remain undelivered for weeks after the drug exposure **(3)**.

A single course of ACS is generally considered to be safe for the fetus. However, concerns have been expressed regarding their short and long-term side effects on the fetus (4) including reduced size and head circumference, increased and prolonged dysregulation of the adrenal axis (5), cognitive and motor impairment **(6)**. Moreover, a correlation between ACS and neonatal hypoglycemia has been recently demonstrated (7,8). Although neonatal hypoglycemia is amenable of successful treatment by care providers, its long-term metabolic and neurological consequences are still matter of debate (9,10).

The aim of this study was to evaluate the determinants of neonatal hypoglycemia in women exposed to ACS for the induction of fetal lung maturation.

## **MATERIALS AND METHODS**

### **Study design and participants**

This is a retrospective multicenter cohort study. Clinical records of all consecutive neonates delivered from 2016 to 2017 at two tertiary care university Hospitals in Italy (University of Parma; University of Naples Federico II) were included in a dedicated merged database. Only neonates exposed to ACS

were included. Women at risk for spontaneous or iatrogenic preterm delivery between 24 0/7 - 33 6/7 or those undergoing to late preterm or early term cesarean between 34 0/7 - 37 6/7 weeks were considered eligible for the study. Indication for planned cesarean delivery <38 weeks included placenta previa and/or accreta, severe pregnancy hypertensive disorders, severe and early fetal growth restriction. In the two institutions participating to this study, ACS included two doses of Betamethasone 12 mg administered intramuscularly 24 hours apart (11).

Exclusion criteria were neonatal congenital anomalies, multiple pregnancy, neonatal hypoxic ischemic encephalopathy or sepsis, maternal diabetes and maternal steroids treatment due to other medical indications.

We defined as early preterm those newborns delivered between 24 0/7 – 33 6/7 weeks while late preterm infants were those delivered between 34 0/7 and 36 6/7 weeks. Optimal ACS administration was defined as an administration between 24 and 7 days before delivery; suboptimal administration was defined as an administration less than 24 hours or more than 7 days before delivery.

All the neonates included in the present study underwent a strict monitoring protocol. Neonatal blood glucose concentrations were measured on capillary blood samples taken by heel-prick lance and analyzed on a blood gas analyzer using the glucose oxidase method. Samples were taken at 1 hour after birth regardless of feeds, then before feeds 3-4 hourly in the first 24 hours, then 3-8 hourly for the next 24 hours. Measurements were discontinued if there were 3 normal blood glucose concentration measurements and no clinical concerns about feeding.

Neonatal hypoglycemia was defined as a glycemic value  $\leq 45$  mg/dl within the first 48 hours of neonatal life (12). The lowest glycemic value found during this interval-time was considered for the purpose of the study.

## **Outcomes**

The primary outcome was the overall incidence of neonatal hypoglycemia in a cohort of women exposed to ACS for the prevention of respiratory distress syndrome. The secondary outcome was to

compare demographics, clinical features and pregnancy characteristics between cases with hypoglycemic vs normoglycemic neonates.

Population birthweight percentiles were retrospectively calculated using Italian data and gestation calculator (13). According to these national neonatal charts, small for gestational age (SGA) neonates were defined as those whose birthweight was below the 10th centile, while large for gestational age (LGA) infants were defined as those whose birthweight was above the 90th centile (13).

### **Statistical analysis**

Statistical analysis was performed using Statistical Package for Social Sciences (SPSS) v. 21.0 (IBM Inc., Armonk, NY, USA). Data are shown as means  $\pm$  standard deviation (SD), or as medians (range), or as numbers (percentage). Univariate comparisons of dichotomous data were performed with the use of the chi-square with continuity correction. Comparisons between groups were performed with the use of the T-test to test group means with SD by assuming equal within-group variances.

To assess the independent predictors of neonatal hypoglycemia baseline characteristics associated with a  $P < 0.05$  in univariate analyses were implemented into a multivariable backward-stepwise regression model with removal criteria of  $P > .1$ . After testing collinearity, correlated variables ( $VIF > 3$ ) were not used simultaneously in the same model (eg. Gestational age at delivery and birthweight). We calculated two-sided p-values. A p-value  $< 0.05$  was considered to indicate statistical significance. This study was reported following the STROBE guidelines (14).

This study has been approved by the local ethics committee (976/2018/OSS/UNIPR)

### **RESULTS**

Over the study period, a total of 99 neonates met the inclusion criteria. Overall, a mean glycaemic value of  $52,24 \pm 32,17$  mg/dl was reported while the incidence of neonatal hypoglycemia was 38.4% (38/99). Neonatal characteristics and main indications to ACS administration are summarized in

Table 1. The incidence of hypoglycemia was significantly different among early preterm, late preterm and term-delivered neonates (60.5% vs. 38.5% vs. 14.3% respectively;  $p=0.002$ ).

An overall rate of optimal ACS administration of 40.4% was reported with 52.5% of deliveries occurring  $>7$  days from ACS administration and 7.1% of them within 24 hours from ACS course.

On Table 2 maternal demographics, pregnancy characteristics and type of ACS exposure between hypo- vs normoglycemic neonates are illustrated. As shown on table 2, neonatal hypoglycemia was more frequent in cases with lower gestational age at delivery, lower birthweight, single partial course and shorter time interval from exposure to delivery.

At multivariable backward stepwise regression including the relevant covariates selected by univariate analysis only the birthweight remained significantly associated with neonatal hypoglycemia (Table 3); in addition, a positive correlation between the neonatal glycaemia (mg/dL) and birthweight (g) was demonstrated by using linear regression ( $y=5,6639x+1914,7$ ;  $R^2 = 0,044$ ;  $p=0.038$ ).

The multivariate regression model including gestational age at delivery did not demonstrate a significant association between this variable and neonatal hypoglycemia (Supplement 1).

## **DISCUSSION**

### **Principal findings**

Our study confirmed that hypoglycemia during the first 48 hours of neonatal life occurs in a large proportion of fetuses exposed to ACS for respiratory distress syndrome (RDS) prevention; in our series a glycemic value below the threshold of 45 mg/dL was noted in more than one third of the neonates with a higher prevalence in preterm newborns.

Furthermore, we found that birthweight is the strongest determinant for neonatal hypoglycemia among a population of women exposed to antenatal steroids while type of ACS exposure (single

partial/ single completed) and interval between ACS administration and delivery does not seem to affect the occurrence of neonatal hypoglycemia.

### **Interpretation**

There are two main mechanisms potentially implicated in neonatal hypoglycemia due to ACS exposure. The first one is corticosteroid-induced hyperglycemia in mothers leading to fetal and neonatal hyperinsulinemia and hypoglycemia due to hyperplasia of fetal pancreatic beta cells (15); the second one, as suggested by some, is mediated by fetal adrenal suppression (16).

On the other hand, previous experimental studies demonstrated that antenatal exposure to corticosteroids may produce the induction of fetal hepatic enzymes involved in the regulation of glucose metabolism (17).

These studies, together with our findings may support the concept that antenatal exposure to steroids can promote substantial changes on the fetal glucose metabolism. A higher insulin resistance in adults exposed to corticosteroids during fetal life has been recently shown in a large RCT (18). On this basis, it is plausible to speculate that in some cases neonatal hypoglycemia or possibly adult hyperglycemia may be considered as a long-term side-effect of ACS administration, possibly mediated by “fetal programming” mechanisms.

Our own observation that a lower birthweight is the strongest determinant of hypoglycemia among neonates exposed to antenatal steroids seems to confirm that the occurrence of hypoglycemia is more likely if the fetal storage of glycogen is absent or reduced (19). Fetal growth restriction rather than prematurity per se has been actually reported as the major risk factor for neonatal hypoglycemia, with an incidence ranging from 17-61% (20) and this may indicate that the body weight composition may affect the risk of neonatal hypoglycemia independently and more importantly than gestational age at delivery. A recent study found that low body fat is the strongest risk factor for neonatal hypoglycemia even in neonates with an appropriate birthweight (21).

In most of the existing studies on the association between prematurity and neonatal hypoglycemia, the net contribution of maternal steroids on the occurrence of neonatal hypoglycemia is difficult to quantify. In women at risk of delivery before 34 gestational weeks in fact ACS are routinely administered, and this mostly precludes to assess the incidence of hypoglycemia among preterm newborns whose mothers were not exposed to steroids (1). Also, in our study including a cohort of women at risk of preterm delivery in whom the antenatal administration of steroids was clinically indicated we lack a control group of women unexposed to betamethasone.

A European cohort study of 4,594 infants found that only 14% of early preterm infants were not exposed to antenatal ACS (22). For this reason, existing literature on metabolic effects of ACS on early preterm infants is mostly based on small retrospective studies with a bias due to a more severe clinical condition requiring delivery before ACS course.

A summary of the studies which have compared the incidence of neonatal hypoglycemia among neonates exposed to ACS compared to non-exposed neonates is provided on Table 4 (8,23-25).

According to this data a higher incidence of neonatal hypoglycemia has been found in neonates whose mothers has been exposed to ACS.

### **Clinical implications**

Our results confirm the need of a strict glycemetic control for neonates exposed to ACS, in particular for those of low birthweight. In our series a higher incidence of hypoglycemia among both early and late preterm neonates was found compared with previous data, probably due to the higher cut-off used in our study for the definition of hypoglycemia. On the other hand, we noted a not negligible incidence of hypoglycemia even in full-term neonates. Among them, strong figures on the incidence of hypoglycemia are lacking as routine blood glucose assessment in asymptomatic newborns is not recommended. No definitive consensus has been actually reached on how to define and when to look for hypoglycemia among full-term neonates. A study by Bromiker et al. (26),

analyzed the incidence of neonatal hypoglycemia among unselected healthy full-term neonates reporting an incidence ranging between 3%-12% according to the cut-off used for hypoglycemia (<40 mg/dl and <47 mg/dl, respectively). No data are available regarding the incidence of hypoglycemia in neonates born after 37 weeks of gestation whose mothers were antenatally exposed to corticosteroids (7).

These observations may suggest a more intensive metabolic surveillance of neonates exposed to ACS, before the occurrence of symptoms of hypoglycemia.

Neonatal hypoglycemia can be considered as a minor side effect if compared to the beneficial effects of ACS administration on neonatal outcome especially for infants born before 34 gestational weeks. After this gestational age, the available evidences show a modest clinical benefit of steroids mainly on morbidity but not on mortality rate compared to the potential risks, including hypoglycemia (2). While hypoglycemia can be easily managed especially in high-intensity care settings, its long-term consequences are still undetermined. The recent CHYLD study (“Children with Hypoglycemia and Their Later Development”) has shown a dose-dependent increased risk of poor executive function and visual motor function at 4 years of age in children who experienced neonatal hypoglycemia (13). However, since hypoglycemia was mostly documented in preterm neonates and since prematurity itself is a major risk factor of poor neurological outcome, the true association between hypoglycemia and neurodevelopmental delay remains matter of investigation (27).

### **Strengths and limitations**

The main limitations of this study are its retrospective design and the small number of neonates included. Moreover, the lack of a control group not exposed to steroids does not allow to assess the net contribution of steroids to the occurrence of neonatal hypoglycemia. However, this was not the main goal of our work. The objective of this study was rather to establish which factors may affect

the incidence of neonatal hypoglycemia among women exposed to ACS for the prevention of respiratory distress syndrome

The main strength of this work is that we have thoroughly examined a list of pregnancy characteristics and variables associated with ACS administration to work out if and how steroids may affect the incidence of hypoglycemia among both preterm and full-term neonates.

In conclusion, our results demonstrated that hypoglycemia after ACS is more likely to occur in neonates with a lower birthweight irrespectively from the interval between the drug exposure and the gestational age at delivery.

On this basis due to the uncertain long-term effects of neonatal hypoglycemia the antenatal administration of steroids should be reserved only to the women at risk of impending preterm delivery where the good of the drug exposure for the offspring clearly outweighs the bad or the unknown (3). Moreover, glycemic control should be carried out in all neonates exposed to ACS particularly in low birthweight neonates and independently from gestational age at delivery and from the time interval between exposure and delivery.

Finally, despite the small size of our study we believe that our findings are worthy to be reported and reassessed on a larger population. Additional investigations and continuous promotion of clinical guidelines are certainly warranted to optimize the administration of antenatal corticosteroids and to minimize the harmful effects on the exposed neonates.

## REFERENCES

1. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. *JAMA*. 1995; 273:413–418
2. Battarbee AN, Ros ST, Esplin MS et al. Optimal timing of antenatal corticosteroid administration and preterm neonatal and early childhood outcomes, *AJOG MFM*, 2019, doi.org/10.1016/j.ajogmf.2019.100077, in press
3. Jobe AH, Goldenberg RL. Antenatal corticosteroids: an assessment of anticipated benefits and potential risks. *Am J Obstet Gynecol*. 2018 Jul;219(1):62-74
4. Brownfoot FC, Crowther CA, Middleton P. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev*, 2008; CD006764.
5. Waffarn F, Davis EP. Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. *Am J Obstet Gynecol*. 2012 Dec;207(6):446-54
6. Melamed N, Asztalos E, Murphy K, et al. Neurodevelopmental disorders among term infants exposed to antenatal corticosteroids during pregnancy: a population- based study. *BMJ Open* 2019;9:e031197. doi:10.1136/ bmjopen-2019-031197
7. Saccone G, Berghella V. Antenatal corticosteroids for maturity of term or near-term fetuses: systematic review and meta-analysis of randomized controlled trials *BMJ* 2016 Oct 12;355: i5044
8. Gyamfi-Bannerman C, Thom EA, Blackwell SC. et al.; NICHD Maternal–Fetal Medicine Units Network Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. *N Engl J Med*. 2016 Apr 7;374(14):1311-20

9. McKinlay CJD, Alsweiler JM, Anstice NS et al.; Children With Hypoglycemia and Their Later Development (CHYLD) Study Team.  
Association of Neonatal Glycemia With Neurodevelopmental Outcomes at 4.5 Years.  
JAMA Pediatr. 2017 Oct 1;171(10):972-983
10. Burns CM, Rutherford MA, Boardman JP, Cowan FM Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycaemia  
Pediatrics. 2008 Jul;122(1):65-74. doi: 10.1542/peds.2007-2822.
11. Royal College of Obstetricians and Gynecologists. Antenatal corticosteroids to reduce neonatal morbidity and Mortality. Green Top Guidelines no. 7 October 2010
12. Cornblath M, Hawdon JM, Williams AF, et al. Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics. 2000;105(5):1141–1145
13. Bertino E, Spada E, Occhi L et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr. 2010; 51:353-61
14. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP for the STROBE Initiative. The strengthening the reporting of the observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-7
15. Pettit KE, Tran SH, Lee E, Caughey AB. The association of antenatal corticosteroids with neonatal hypoglycaemia and hyperbilirubinemia The J of Maternal fetal and Neonatal Medicine 2014;27:683-686.
16. Aydin M, Deveci U, Hakan N. Neonatal hypoglycemia associated with the antenatal corticosteroids may be secondary to fetal adrenal suppression. J Matern Fetal Neonatal Med. 2015 May;28(8):892

17. Ni L, Pan Y, Tang C, Xiong W, Wu X, Zou C. Antenatal exposure to betamethasone induces placental 11 $\beta$ -hydroxysteroid dehydrogenase type 2 expression and the adult metabolic disorders in mice. 2018 PLoS ONE 13(9): e0203802
18. Dalziel SR, Walker NK, Parag V et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. *Lancet*. 2005 May 28-Jun 3;365(9474):1856-62
19. Mitanchez D. Glucose Regulation in Preterm Newborn Infants. *Horm Res* 2007; 68:265–271
20. Hosagasi NH, Aydin M, Zenciroglu A, Ustun N, Beken S Incidence of hypoglycemia in newborns at risk and an audit of the 2011 American academy of pediatrics guideline for hypoglycemia *Pediatr Neonatol*. 2018 Aug;59(4):368-374
21. Shaw M, Lutz T, Gordon A. Does low body fat percentage in neonates greater than the 5<sup>th</sup> percentile birthweight increase the risk of hypoglycemia and neonatal morbidity? *J Paediatr Child Health*. 2019 Apr 11. doi: 10.1111/jpc.14433
22. Norman M, Piedvache A, Borch K, et al. Association of short antenatal corticosteroid administration-to-birth intervals with survival and morbidity among very preterm infants: results from the EPICE cohort. *JAMA Pediatr* 2017;171: 678-86.
23. Kuper SG, Baalbaki S, Parrish MM, Jauk V, Harper AT, Harper LM Association between antenatal corticosteroids and neonatal hypoglycaemia in indicated early preterm births *J Matern Fetal Neonatal Med*.
24. Porto AM, Coutinho IC, Correia JB, Amorim MM. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomized clinical trial. *BMJ* 201; 342: d1696
25. Ramadan MK, Hussein G, Saheb W, Rajab M, Mirza FG. Antenatal corticosteroids in late preterm period: a prospective cohort study. *J Neonat-Perinat Med*. 2016:15-22

26. Bromiker R, Perry A, Kasirer Y, Einav S, Klinger G, Levy-Khademi F. Early neonatal hypoglycemia: incidence of and risk factors. A cohort study using universal point of care screening. *J Matern Fetal Neonatal Med.* 2017 Oct 26:1-7
  
27. Goode RH, Rettiganti M, Li J, Lyle RE, Whiteside-Mansell L, Barrett KW, Casey PH. Developmental Outcomes of Preterm Infants with Neonatal Hypoglycemia. *Pediatrics.* 2016 Dec;138(6): e20161424



**Table 1.** Neonatal outcome, characteristics and main indications for antenatal corticosteroids (ACS) course

	n=99
<b>Neonatal outcome</b>	
GA at ACS course (weeks)	32,06±3,33
GA at delivery (weeks)	34,83± 3,53
Birthweight (g)	2210,61±871,22
Birthweight percentile	38,15±27,41
Neonatal Hypoglycemia	38(38.4)
Mean glycemc value (m/dl)	52,24±32,17
<b>Characteristics of ACS course</b>	
Complete ACS course	70(70.7)
Interval from exposure to delivery (weeks)	2,77±3,18
Repeated ACS course	13(13.1%)
Optimal ACS course	34(34.3)
<b>Main indications for ACS course</b>	
Preeclampsia/IUGR	32(32.4)
p-PROM	12(12.1)
Preterm labor	30(30.3)
Placenta previa	19(19.2)
Vaginal bleeding	3(3.0)
Elective Caesarean Section	3(3.0)

GA= Gestational Age, p-PROM= preterm Premature Rupture of Membranes; IUGR=Intra-Uterine Growth Restriction

**Table 2.** Secondary outcome

	<b>Hypoglycemia (n=38)</b>	<b>Normoglycemia (n=61)</b>	<b>p-value</b>
Maternal Age	31,94±6,53	29,85±7,10	0.14
Caucasian	26(68,4%)	47(77,0%)	0,34
Gestational age at delivery	33,06 ±3,37	35,94± 3,17	<0,0001
Fetal gender (M:F)	19:19	30:31	0,93
Caesarean Section	9 (23,7%)	26(42,6%)	0,06
Neonatal weight	1747,28± 815,29	2499,24± 780,51	<0,0001
Birthweight percentile	32,00 ±26,08	40,55±27,35	0,17
Preterm delivery (<37 Gestational weeks)	33(86,8%)	31(50,8)	<0,001
Small for Gestational Age (SGA)	12(31,6%)	11(18,0%)	0,12
Large for Gestational Age (LGA)	0	3(4,9%)	0,16
Gestational Age at I dose	31,21 ±3,21	32,59± 3,32	0,04
Interval time from administration to delivery	1,85 ±2,59	3,34 ±3,39	0,02
Single partial course	9(23,7%)	5(8,2%)	0,03
Repeated course	6(15,9%)	7(11,5%)	0,53
Optimal course	13(34,21%)	21(34,42%)	0,98

**Table 3.** Multivariate backward stepwise regression analysis for predictors of neonatal hypoglycemia

<b>Variable</b>	<b>OR (95%CI)</b>	<b>p-value</b>
Birthweight (Kg)	0,4 (-1,16/-0,04)	0,038
Time interval from exposure to delivery (weeks)	1,00 (-0,20-0,20)	0,99
Single Partial Course	2,00 (-0,62-2,00)	0,30
Preterm delivery (<37 gestational weeks)	1,97 (-0,77-2,13)	0,36

**Table 4.** Summary of existing studies on neonatal hypoglycemia after antenatal corticosteroid (ACS) administration

<b>Study, year</b>	<b>Study Type</b>	<b>Neonates exposed to ACS (n)</b>	<b>Definition of hypoglycemia</b>	<b>Hypoglycemia in exposed neonates (%)</b>	<b>Hypoglycemia in non-exposed neonates (%)</b>
<i>Early preterm (24+0-33+6)</i>					
Kuper et al. <sup>21</sup> , 2017	Retrospective cohort study	604	<40 mg/dL within the first 48 hours of life	23.0	16.1
<i>Late preterm (34+0-36+6)</i>					
Porto et al. <sup>22</sup> , 2011	Double blind RCT	143	Not stated	10.5	7.0
Gyamfi-Bannerman et al. <sup>6</sup> , 2016	Double blind RCT	1427	<40 mg/dL at any time	24.0	15.0
Ramadan et al. <sup>23</sup> , 2016	Prospective cohort study	64	<40 mg/dL within 1 hour of life	20.3	10.9

# The JOURNAL of PEDIATRICS

3333 Burnet Avenue, MLC-3021  
Cincinnati, OH 45229-3039  
journal.pediatrics@cchmc.org  
(513) 636-7140 513-636-7141 (fax)  
www.jpeds.com  
http://ees.elsevier.com/jped

## AUTHORSHIP AGREEMENT AND CONTRIBUTION

Please submit one (1) form signed by ALL authors

All submissions to *The Journal of Pediatrics* must adhere to and provide information in accordance with the International Committee of Medical Journal Editors' (ICMJE) [recommendations](#) and [guidelines](#) pertaining to authorship criteria. Only individuals who fulfill the ICMJE's conditions for authorship should be included in the author list. Individuals who have contributed to the study, but do not meet the requirements for authorship, should be included in the Acknowledgments section.

By signing this authorship agreement and contribution form, authors agree that

- The manuscript represents original work and there are no prior publications or submissions with overlapping information, OR
- Any prior publications with overlapping information, including studies and patients have been disclosed and a copy of the work(s) uploaded with this submission;
- The manuscript has not been and will not be submitted to any other journal while it is under consideration by *The Journal of Pediatrics*; and
- All conflicts of interest, real and perceived, and funding sources have been reported

**Article title: Determinants of neonatal hypoglycemia after Antenatal administration of Corticosteroids (ACS) for lung maturation: data from two referral Centers and review of the literature**

**Date submitted: 29.11.2019**

**Corresponding author:** Tullio Ghi

**Email:** tullioghi@yahoo.com

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Conceptualization/design | <input type="checkbox"/> Funding acquisition      |
| <input checked="" type="checkbox"/> Methodology              | <input checked="" type="checkbox"/> Data curation |
| <input type="checkbox"/> Investigation                       | <input type="checkbox"/> Formal analysis          |
| <input checked="" type="checkbox"/> Supervision/oversight    | <input type="checkbox"/> Resources                |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript
- Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes
- No

4) I agree to be accountable for all aspects of the work

- Yes
- No

Tullio Ghi

29.11.2019

*Continues on next page*

Signature (sign or type name)

Date

**Author:** Elvira di Pasquo

**Email:** elviradp1@hotmail.it

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Conceptualization/design | <input type="checkbox"/> Funding acquisition        |
| <input checked="" type="checkbox"/> Methodology              | <input checked="" type="checkbox"/> Data curation   |
| <input checked="" type="checkbox"/> Investigation            | <input checked="" type="checkbox"/> Formal analysis |
| <input type="checkbox"/> Supervision/oversight               | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript
- Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes  No

4) I agree to be accountable for all aspects of the work

- Yes  No

Elvira di Pasquo

29.11.2019

Signature (sign or type name)

Date

**Author:** Gabriele Saccone

gabriele.saccone.1990@gmail.com

**Email:**

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Conceptualization/design | <input type="checkbox"/> Funding acquisition        |
| <input checked="" type="checkbox"/> Methodology              | <input checked="" type="checkbox"/> Data curation   |
| <input checked="" type="checkbox"/> Investigation            | <input checked="" type="checkbox"/> Formal analysis |
| <input type="checkbox"/> Supervision/oversight               | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript
- Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes  No

4) I agree to be accountable for all aspects of the work

- Yes  No

Gabriele Saccone  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Author:** Andrea Dall'Asta

**Email:** andrea.dallasta1@gmail.com

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |   |   |
|---|---|
| <input type="checkbox"/> Conceptualization/design         | <input type="checkbox"/> Funding acquisition        |
| <input checked="" type="checkbox"/> Methodology           | <input checked="" type="checkbox"/> Data curation   |
| <input checked="" type="checkbox"/> Investigation         | <input checked="" type="checkbox"/> Formal analysis |
| <input checked="" type="checkbox"/> Supervision/oversight | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript
- Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes  No

4) I agree to be accountable for all aspects of the work

- Yes  No

Andrea Dall'Asta  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Author:** Laura Angeli

**Email:** larua.a@gmail.com

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |   |   |
|---|---|
| <input type="checkbox"/> Conceptualization/design | <input type="checkbox"/> Funding acquisition        |
| <input type="checkbox"/> Methodology              | <input checked="" type="checkbox"/> Data curation   |
| <input checked="" type="checkbox"/> Investigation | <input checked="" type="checkbox"/> Formal analysis |
| <input type="checkbox"/> Supervision/oversight    | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript
- Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes  No

4) I agree to be accountable for all aspects of the work

- Yes  No

Laura Angeli  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Author:** Stefania Fieni

**Email:** fieniste@hotmail.it

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |   |   |
|---|---|
| <input type="checkbox"/> Conceptualization/design         | <input type="checkbox"/> Funding acquisition        |
| <input type="checkbox"/> Methodology                      | <input type="checkbox"/> Data curation              |
| <input type="checkbox"/> Investigation                    | <input checked="" type="checkbox"/> Formal analysis |
| <input checked="" type="checkbox"/> Supervision/oversight | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript  
 Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes     No

4) I agree to be accountable for all aspects of the work

- Yes     No

Stefania Fieni  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Author:** Vincenzo Berghella  
Vincenzo.Berghella@jefferson.edu

**Email:**

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Conceptualization/design | <input type="checkbox"/> Funding acquisition        |
| <input checked="" type="checkbox"/> Methodology              | <input type="checkbox"/> Data curation              |
| <input type="checkbox"/> Investigation                       | <input checked="" type="checkbox"/> Formal analysis |
| <input checked="" type="checkbox"/> Supervision/oversight    | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript  
 Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes     No

4) I agree to be accountable for all aspects of the work

- Yes     No

Vincenzo Berghella  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Author:** Tiziana Frusca

**Email:** fruscatiziana@gmail.com

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Conceptualization/design | <input type="checkbox"/> Funding acquisition        |
| <input checked="" type="checkbox"/> Methodology              | <input type="checkbox"/> Data curation              |
| <input type="checkbox"/> Investigation                       | <input checked="" type="checkbox"/> Formal analysis |
| <input checked="" type="checkbox"/> Supervision/oversight    | <input type="checkbox"/> Resources                  |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript  
 Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes  No

4) I agree to be accountable for all aspects of the work

- Yes  No

Tiziana Frusca  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Author:** Magnani Cinzia

**Email:** CMagnani@ao.pr.it

I confirm that I am an author on the above mentioned manuscript, which is currently being submitted to *The Journal of Pediatrics*. My authorship contribution consisted of the following (**note:** authors must meet all four conditions):

1) Substantial contributions to the study, including (please mark all that are applicable):

- |   |  |
|---|--|
| <input type="checkbox"/> Conceptualization/design         | <input type="checkbox"/> Funding acquisition |
| <input type="checkbox"/> Methodology                      | <input type="checkbox"/> Data curation       |
| <input checked="" type="checkbox"/> Investigation         | <input type="checkbox"/> Formal analysis     |
| <input checked="" type="checkbox"/> Supervision/oversight | <input type="checkbox"/> Resources           |

2) Participation in the writing and/or revision, including:

- Writing – drafting the initial manuscript  
 Writing – review or editing of the manuscript

3) I gave final approval of the version to be published

- Yes  No

4) I agree to be accountable for all aspects of the work

- Yes  No

Cinzia Magnani  
**Signature (sign or type name)**

29.11.2019  
**Date**

**Suppl.1.** Multivariate backward stepwise regression analysis for predictors of neonatal hypoglycemia including gestational age at delivery

<b>Variable</b>	<b>p-value</b>
Gestational age at delivery	0,07
Time interval from exposure to delivery (weeks)	0,94
Single Partial Course	0,26
Preterm delivery (<37 gestational weeks)	0,29